HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Beijing Wantai Biological (603392.CH) - After A 3839% Rally, Let's Look at Some Concerns

Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns

CanSino Biologics (6185.HK) - Will the COVID-19 Vaccine Be the Turning Point?

Ping An Good Doctor (1833.HK) - It Is the Time to Look at Some Concerns

Jinxin Fertility (1951.HK) - The New Policy, the Logic and the Risk Factors

Lepu Medical Technology A (300003 CH) - Does Not Have High Moat

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

Qingdao Haier Biomedical  Lt / Equity Bottom-Up

<p>Recently, <a href="https://www.smartkarma.com/entities/qingdao-haier-biomedical-co-ltd-a" target="_blank" data-smartkarma-citation="entities:30352:1" rel="noopener">Qingdao Haier Biomedical Co., Ltd.-A (688139 CH)</a> released the performance announcement in 2020. Haier is expected to achieve the net income attributed to shareholders in 2020 of RMB379 million to RMB425 million, up 3713% to 3994% YoY. The Company's non-recurring profit and loss increased largely YoY due to the disposal of subsidiary as well as the increase in financing income. Net income after deducting non-recurring gains and losses is expected to reach RMB312 million to RMB354 million, up 87% to 112% YoY. Meanwhile, in 2020Q4, net income attributed to shareholders is expected to be RMB107 to RMB152 million, up 119.11%-212.54% YoY. Net income after deducting non-recurring gains and losses is expected to reach RMB90 million to RMB132 million, up 84.18% to 169.47% YoY. The results beat the market expectations.</p>

Recently, Qingdao Haier Biomedical Co., Ltd.-A (688139 CH) released the performance announcement in 2020. Haier is expected to achieve the net income attributed to shareholders in 2020 of RMB379 million to RMB425 million, up 3713% to 3994% YoY. The Company's non-recurring profit and loss increased largely YoY due to the disposal of subsidiary as well as the increase in financing income. Net income after deducting non-recurring gains and losses is expected to reach RMB312 million to RMB354 million, up 87% to 112% YoY. Meanwhile, in 2020Q4, net income attributed to shareholders is expected to be RMB107 to RMB152 million, up 119.11%-212.54% YoY. Net income after deducting non-recurring gains and losses is expected to reach RMB90 million to RMB132 million, up 84.18% to 169.47% YoY. The results beat the market expectations.

Haier Biomedical (688139.CH) - Just Been Included in the FTSE GEIS, Time to Follow